PER 0.00% 10.0¢ percheron therapeutics limited

News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-5

  1. 4,149 Posts.
    Lol dream on Gassy....nobody wants what Anp has got,
    16 years of failure in that department proves that.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.